CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Beta Bionics Q3 adjusted EBITDA misses estimates

By Reuters News


Overview

  • US diabetes device maker's Q3 net sales rose 30%, beating analyst expectations

  • Q3 adjusted EBITDA missed analyst estimates; operating loss was a slight miss


Outlook

  • Beta Bionics raises 2026 revenue guidance to $124 mln-$126 mln from $121 mln-$126 mln

  • Company expects up to $8.5 mln in Q4 2026 revenue deferral as customers await Mint launch

  • Beta Bionics expects Mint to recapture any lost Q4 2026 revenue during 2027


Result Drivers

  • PBP CHANNEL GROWTH - Co said Pharmacy Benefit Plan channel net sales rose 118% year-on-year, driving overall sales growth

  • NEW PATIENT STARTS - Co reported mid-single digit percentage increase in new patient starts versus prior quarter

  • GROSS MARGIN IMPROVEMENT - Co said gross margin rose 179 basis points year-on-year to 57.3%


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Net sales

Beat

$35.51 mln

$34.72 mln (14 Analysts)

Q3 Loss Per Share

$0.52

Q3 Net Loss

$24.35 mln

Q3 Adjusted EBITDA

Miss

-$18.91 mln

-$18.46 mln (10 Analysts)

Q3 Income from Operations

Slight Miss*

-$26.61 mln

-$26.42 mln (13 Analysts)

Q3 Gross Profit

$20.33 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Beta Bionics, Inc. is $25.00, about 21.9% above its October 26 closing price of $20.51


Reuters Recommended Reads

  • Oct 26 - Acumen Pharmaceuticals posts smaller than expected Q3 loss

  • Oct 26 - Medifast Q3 revenue falls on fewer active earning coaches

  • Oct 27 - FDA warns Amgen over cancer drug promotional video


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.